[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastro-intestinal-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastro-intestinal-disorder":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,39,61,77,106,126,157,190,214,237,263],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":16,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100490283","phase-1-feasibility-safety-and-potential-efficacy-of-fecal-microbiota-transplantation-fmt-for-gastrointestinal-dysfunction-in-children-following-hematopoietic-cell-transplant-hct-100490283",false,"NCT05664113","Feasibility, Safety, and Potential Efficacy of Fecal Microbiota Transplantation (FMT) for Gastrointestinal Dysfunction in Children Following Hematopoietic Cell Transplant (HCT).","Inclusion Criteria:\n\n* Age \\\u003C 22 years old.\n* Received an allogeneic HCT greater than or equal to 30 days prior to enrollment\n* Diagnosed with one of the following conditions:\n\n  1. Steroid-resistant gut a GvHD (defined as GI symptoms that do not improve within 5 days after initial steroid therapy, \\>\u002F= 1mg\u002Fkg of prednisolone) OR\n  2. Steroid-dependent gut a GvHD (defined as the presence of a response to methylprednisolone 2 mg\u002Fkg\u002Fday but relapsing when an attempt was made to taper steroid treatment).\n\n     OR\n  3. Current or prolonged GI dysfunction following HCT, defined as having diarrhea or loose stools \\>\u002F= 4 weeks with at least one of the following:\n\n     1. Requiring NG or G-tube feeds\n     2. Requiring TPN or IVF for more than 4 weeks\n     3. Diagnosis of gastroparesis by GI specialist documented in the medical record\n* Willing and able to provide informed assent\u002Fconsent\n\nExclusion Criteria:\n\n* Patient is at risk for aspiration pneumonia\n* History of anaphylactic allergy to foods that are not excluded from the stool donor diet\n* Female participant who is pregnant or nursing\n* History of previous FMT\n* Intra-abdominal surgery within 4 weeks of enrollment\n* At increased risk for peritonitis: presence of intra-abdominal devices (G-or GJ-tubes are acceptable), receiving peritoneal dialysis, or ascites\n* Concurrent abdominal radiation therapy\n* Any acute or chronic illness\u002Fcondition as well as medication that in the opinion of the investigator puts the subject at greater risk from FMT or may confound the study results.","ALL","22 Years",{"count":18,"type":19},10,"ESTIMATED","INTERVENTIONAL",[22],"PHASE1","The study participant is being asked to take part in this clinical trial, a type of research study, because the participant has Gastrointestinal (GI) symptoms following a Hematopoietic Cell Transplant (HCT).\n\nPrimary Objective\n\n* To determine the safety and feasibility of FMT for treating a GvHD of the gut following HCT.\n* To determine the safety and feasibility of FMT for treating HCT induced gut dysfunction.\n\nSecondary Objectives\n\n* To assess the potential efficacy of FMT for treating a GvHD of the gut following HCT.\n* To assess the potential efficacy of FMT for treating HCT induced gut dysfunction.",[25],"Gastro-Intestinal Disorder","RECRUITING","2026-06-15",{"date":29,"type":30},"2026-06-17","ACTUAL",{"date":32,"type":30},"2025-07-07",{"date":34,"type":19},"2028-12-31",{"name":36,"class":37},"St. Jude Children's Research Hospital","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":46,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":38},"100636420","evaluation-of-hepato-pancreato-biliary-100636420","NCT07565454","Evaluation of Hepato-Pancreato-Biliary","Evaluation of HPB or Advanced GI Surgery Fellowship Training","Inclusion Criteria:\n\n1. Current, and past fellows of Fellowship Council(FC )sponsored fellowship including Americas Hepato-Pancreato-Biliary Association(AHPBA)-accredited HPB and Advanced GI surgery fellowship.\n2. Current senior surgeons involved in Fellowship Council(FC) fellowship training.\n\nExclusion Criteria:\n\nFellows who choose not to respond to the survey",true,{"count":48,"type":19},100,"OBSERVATIONAL","Some reports cite over 80% of surgery residency graduates are seeking additional training to improve on their experiences to be ready for practice. The Fellowship Council created several fellowship tracts including HPB (Hepato-Pancreato-Biliary),Advanced GI (gastrointestinal) and Minimally Invasive surgery to address this issue, and bridge the gap in training between residency and real life practice in those that seek a practice in HPB or complex GI surgery, respectively. By the end of fellowship, the core goal is to make the graduating fellows ready for independent practice in HPB or complex GI surgery cases.",[25],"2026-06-08",{"date":54,"type":30},"2026-06-10",{"date":56,"type":30},"2021-04-01",{"date":58,"type":19},"2028-01",{"name":60,"class":37},"Methodist Health System",{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":68,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":70,"conditions":71,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":72,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":76,"locationsCount":38},"100630949","advanced-gastroinstestinalgi-surgery-training-in-residency-and-fellowship-100630949","NCT07494318","Advanced GastroInstestinal(GI) Surgery Training in Residency and Fellowship.","Advanced GastroInstestinal(GI) Surgery Training in Residency and Fellowship Interest Survey for 4th and 5th Year General Surgical Residents.","Inclusion Criteria:\n\nAll fourth and fifth year general surgery residents in accredited Accreditation Council for Graduate Medical Education(ACGME) general surgery residency programs in the United States.\n\nExclusion Criteria:\n\nAll junior general surgical residents (third year residents through interns) will be excluded from the study.",{"count":69,"type":19},260,"The aim of this anonymous survey is to identify who teaches GI procedures to general surgical residents during residency training and understand the need as well as desire for an Advanced Surgical GI fellowship amongst senior surgical residents. We also hope to identify the self-reported level of comfort of senior general surgery residents in completing both common and complex GI procedures.",[25],{"date":54,"type":30},{"date":74,"type":30},"2018-08-02",{"date":58,"type":19},{"name":60,"class":37},{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":15,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100504322","gastroparesis-registry-4-100504322","NCT05846802","Gastroparesis Registry 4","Gastroparesis Registry 4 (GpR4): Improving the Understanding of Gastroparesis and Functional Dyspepsia","GpR4","Inclusion Criteria:\n\n* Age at least 18 years at initial screening visit\n* Symptoms of Gp and\u002For FD of at least 12-weeks duration with varying degrees of nausea, vomiting, early satiety, postprandial fullness, abdominal pain, abdominal burning. Thus, patients can enter the GpR4 registry primarily with abdominal pain suggesting FD-Epigastric Pain Syndrome.\n* Successful completion of gastric emptying scintigraphy of solids using the 4-hour Egg Beaters® protocol (or equivalent generic liquid egg white meal) within the last 9 months\n* Negative upper endoscopy or upper radiographic GI series within 5 years of registration\n\nExclusion Criteria:\n\n* Use of narcotic analgesics greater than three days per week\n* Presence of other conditions that could explain the patient's symptoms such as:\n* Pyloric or intestinal obstruction as evidenced by EGD, UGI, or Abdominal CT\n* Active inflammatory bowel disease\n* Known eosinophilic gastroenteritis or eosinophilic esophagitis\n* Primary neurological conditions that can cause nausea and vomiting such as increased intracranial pressure, space occupying or inflammatory\u002Finfectious lesions\n* Acute or chronic renal failure (serum creatinine \\>3 mg\u002FdL) and\u002For on hemodialysis or peritoneal dialysis\n* Acute liver failure or advanced liver disease (Child's B or C; a Child-Pugh-Turcotte (CPT) score of ≥7)\n* Pancreatic disorder if present on pancreatic imaging or pancreatic function testing\n* Prior gastric surgery including total or subtotal (near complete) gastric resection, esophagectomy, gastrojejunostomy, gastric bypass, gastric sleeve, pyloroplasty, pyloromyotomy, or any fundoplication (Nissen, Tor)\n* Any other condition, which in the opinion of the investigator, could explain the symptoms or interfere with study requirements\n* Females who are pregnant. A urine pregnancy test is routinely obtained on all females immediately prior to gastric emptying procedures.\n* Inability to comply with or complete the gastric emptying scintigraphy test (including allergy to eggs)\n* Inability to obtain informed consent","18 Years","85 Years",{"count":88,"type":19},250,"The Gastroparesis Registry 4 (GpR4) is an observational study of patients with symptoms of gastroparesis (Gp) and functional dyspepsia (FD) with either delayed or normal gastric emptying. To better understand these disorders, this registry will capture demographic, clinical, physiological, questionnaire, and patient outcome data to characterize the patients and their clinical course. Participants will complete several questionnaires, complete a nutrient drink test and have a gastric emptying study.",[91,92,93,94,95,25],"Gastroparesis","Gastroparesis Nondiabetic","Gastroparesis Due to Diabetes Mellitus Type I","Gastroparesis Due to Diabetes Mellitus Type II","Functional Disorder of Gastrointestinal Tract","2026-03-30",{"date":98,"type":30},"2026-04-03",{"date":100,"type":30},"2024-09-20",{"date":102,"type":19},"2027-04-30",{"name":104,"class":37},"Johns Hopkins Bloomberg School of Public Health",6,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":15,"minAge":113,"maxAge":4,"enrollmentInfo":114,"targetDuration":115,"studyType":49,"phases":4,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":38},"100630627","endoscopic-retrograde-cholangiopancreatography-100630627","NCT07490132","Endoscopic Retrograde Cholangiopancreatography","Endoscopic Retrograde Cholangiopancreatography Patient Registry","Inclusion Criteria:\n\nPatients \\>15 years Included in MDI's Registry Underwent ERCP between January 1, 2000 through December 31, 2025\n\nExclusion Criteria:\n\nPatients \\\u003C15 years Patients in which cannulation was via a surgical anastomosis Patients in which cannulation was not attempted due to gastric outlet obstruction, the main papilla not found, or the minor papilla was not found will be excluded.","15 Years",{"count":48,"type":19},"25 Years","The risk of post-endoscopic retrograde cholangiopancreatography(ERCP) pancreatitis(PEP) is influenced by patient and procedure-related factors. Strategies to decrease PEP(Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis) are of great importance.",[25],"2026-03-18",{"date":120,"type":30},"2026-03-24",{"date":122,"type":19},"2026-02",{"date":124,"type":19},"2028-02",{"name":60,"class":37},{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":15,"minAge":85,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":20,"phases":137,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":156},"100620296","video-tutorial-and-oral-explanation-vs-oral-explanation-alone-in-colonoscopy-preparation-100620296","NCT07355777","Video Tutorial and Oral Explanation Vs Oral Explanation Alone in Colonoscopy Preparation","Prospective Multicenter Randomized Trial Comparing Oral Explanation Alone and With Video Tutorial for Bowel Preparation Quality and Adenoma Detection","PREPACOTUTO","Inclusion Criteria:\n\n* Consecutive patients undergoing their first colonoscopy for gastrointestinal symptoms, family history of CRC or suspected CRC.\n* Ability to use the internet and a link to a video.\n* Life expectancy over three months.\n* Patient ≥ 18 years old, requiring a colonoscopy procedure.\n\nExclusion Criteria:\n\n* Patient with any psychiatric or psychological disorder that does not allow them a properd understanding and follow-up of the study.\n* Patient without internet access.\n* Patient requiring a colonoscopy procedure in emergency","80 Years",{"count":136,"type":19},574,[138],"NA","Colonoscopy which is the standard examination for the exploration of the colon and rectum is performed very frequently.\n\nColon preparation before the examination is an essential step and pescription of the colonic preparation is carried out by the gastroenterologist.\n\nHowever, despite a standardized explanation of the colon preparation, there is heterogeneity in understanding the colonic preparation, which in some cases compromises the quality of the colonoscopy examination. This clinical study aims to investigate whether an explanation of colonic preparation by tutorial films would increase the quality of colon preparation and would reach the recommendations of the Société française d'endoscopie digestive (SFED) in 2019.",[141,25],"Colonoscopy",[143,144,145,146],"colon preparation","colonoscopy","gastro-intestinal disorder","tutorial","2026-01-13",{"date":149,"type":30},"2026-01-21",{"date":151,"type":30},"2025-04-01",{"date":153,"type":19},"2026-03-31",{"name":155,"class":37},"Centre Hospitalier Saint Joseph Saint Luc de Lyon",5,{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":15,"minAge":85,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":20,"phases":166,"briefSummary":167,"conditions":168,"keywords":173,"overallStatus":179,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":189},"100620017","undiluted-and-diluted-nutrition-100620017","NCT07352150","Undiluted and Diluted Nutrition","The Influence of Diluted and Undiluted Enteral Nutrition on Nutritional Tolerance in Critically Ill Patients After Gastrointestinal Surgery - a Randomized Controlled Trial","Inclusion Criteria:\n\nAdults, ≥18, Scheduled for major abdominal surgery requiring ICU admission Having access to the GI tract (gastric or jejunal) Planned to be fed enterally\n\nExclusion Criteria:\n\nPatients unable to give informed consent After emergency surgeries Without access to the GI tract Individuals with contraindications to EN, such as short bowel syndrome, uncompensated shock, acidosis (pH \\\u003C 7.1; lactate \\> 5 mmol\u002Fl), bleeding from the upper GI tract, obstruction, intestinal ischemia, abdominal compartment syndrome Patients with symptomatic gastro-esophageal reflux Expected ICU stay \\\u003C 3 days Pregnancy and lactation",{"count":165,"type":19},80,[138],"Adult patients after elective major abdominal surgeries who are planned to be admitted to the Intensive Care Unit (ICU) can be included in the trial. Each patient will be fed via the gastrointestinal tract. Half of the patients will receive enteral nutrition (EN) with additional fluids, and the rest will receive undiluted EN. The primary aim of this study is to assess feeding intolerance in both patient groups.",[169,170,171,25,172],"Critical Illness","Gastro Intestinal Surgery","Enteral Feeding Intolerance","Quality of Lifte",[174,175,176,177,178],"Zonulin","Intestinal fatty-acid binding protein (I-FABP)","Ketones","enteral feeding","GNAK","NOT_YET_RECRUITING","2026-01-11",{"date":182,"type":30},"2026-01-20",{"date":184,"type":19},"2026-02-02",{"date":186,"type":19},"2027-09-30",{"name":188,"class":37},"John Paul II Catholic University of Lublin",2,{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":46,"sex":15,"minAge":197,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":38},"100589614","naza---nottinghamastra-zeneca-prospective-ibd-cohort-study-100589614","NCT06956703","NAZA - Nottingham\u002FAstra ZenecA Prospective IBD Cohort Study","NAZA","Inclusion Criteria:\n\n1\\. Provision of signed and dated, written informed consent before any study specific procedures\n\nAND\n\n2a. Patients of at least 16 years of age with active Crohn's disease defined as: CRP \\> = 5 mg\u002FL OR FCP \\> = 250 μg\u002Fg OR Visible ulcerations on ileocolonoscopy with a total SES-CD \\> = 7, or \\> = 4 if disease is confined to the terminal ileum OR visable active disease on cross-sectional imaging. Are switching to a new mechanism of action (MOA) onto anti-TNF therapy or ustekinumab or upadacitinib\n\nOR\n\n2b. Patients of at least 16 years (no upper age limit) with active UC defined as: CRP \\> = 5 mg\u002FL OR FCP \\> = 250 μg\u002Fg OR Mayo endoscopy subscore \\> = 2. Are switching to a new mechanism of action (MOA) onto either anti-TNFα therapy or vedolizumab\n\nOR\n\n2c. Non-IBD participants who are attending for a lower GI colonoscopy at any participating site. On any hospital\u002F medical\u002F clinical screening list or any other appropriate list with no pathology found on examination.\n\nExclusion Criteria:\n\n1. Inability to give informed consent\n2. Any positive result from previous screening for serum hepatitis B surface antigen, hepatitis C or human immunodeficiency virus (HIV)\n3. An ongoing infection requiring treatment\n4. Clinical evidence of active COVID infection and\u002For evidence of active COVID determined by local standard care procedures\n5. Participation in a clinical study with pharmacological intervention within 3 months prior to Baseline visit.\n6. Current diagnosis of cancer\n7. Having received a solid organ or stem cell transplant\n8. Having received a transfusion of blood, plasma, or platelets within 120 days prior to enrolment\n9. Confirmed pregnancy at time of enrolment\n10. For non-IBD participants: A prior history of IBD (CD, UC, microscopic colitis, indeterminate colitis or IBD unspecified)\n11. Clinical judgement by the investigator that the patient should not participate in the study\n12. Under 16yrs of age","16 Years",{"count":199,"type":19},240,"The goal of this observational study is to learn about the comparisons of inflammatory markers between IBD and non-IBD (control) participants.\n\nThe main question it aims to answer is:\n\nAre there differences in inflammatory markers between IBD and non-IBD (control) participants.",[25,202,203,204],"Crohn Disease","Ulcerative Colitis","Inflammatory Bowel Diseases","2025-05-22",{"date":207,"type":30},"2025-05-29",{"date":209,"type":30},"2022-12-12",{"date":211,"type":19},"2027-02-28",{"name":213,"class":37},"University of Nottingham",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":162,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":15,"minAge":85,"maxAge":134,"enrollmentInfo":220,"targetDuration":4,"studyType":20,"phases":222,"briefSummary":223,"conditions":224,"keywords":227,"overallStatus":179,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":235,"locationsCount":156},"100555803","diluted-and-undiluted-enteral-nutrition-100555803","NCT06516835","Diluted and Undiluted Enteral Nutrition","Inclusion Criteria:\n\n* Scheduled for major abdominal surgery requiring ICU admission\n* Having access to the GI tract (gastric or jejunal)\n* Planned to be fed enterally\n\nExclusion Criteria:\n\n* Patients unable to give informed consent\n* After emergency surgeries\n* Without access to the GI tract\n* Individuals with contraindications to EN, such as short bowel syndrome, uncompensated shock, acidosis (pH \\\u003C 7.1; lactate \\> 5 mmol\u002Fl), bleeding from the upper GI tract, obstruction, intestinal ischemia, abdominal compartment syndrome\n* Patients with symptomatic gastro-esophageal reflux\n* Expected ICU stay \\\u003C 3 days\n* Pregnancy and lactation",{"count":221,"type":19},60,[138],"Adult patients after elective major abdominal surgeries who are planned to be admitted to the Intensive Care Unit (ICU) can be included in the trial.\n\nEach patient will be fed via the gastrointestinal tract. Half of the patients will receive enteral nutrition (EN) with additional fluids, and the rest will receive undiluted EN.\n\nThe primary aim of this study is feeding intolerance assessment in both groups of patients.",[169,225,171,25,226],"Surgery","Quality of Life",[174,175,176,228],"Microbiome","2024-07-24",{"date":231,"type":30},"2024-07-26",{"date":233,"type":19},"2025-01-02",{"date":102,"type":19},{"name":236,"class":37},"Medical University of Lublin",{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":241,"acronym":242,"eligibilityCriteria":243,"healthyVolunteers":46,"sex":15,"minAge":85,"maxAge":244,"enrollmentInfo":245,"targetDuration":4,"studyType":20,"phases":247,"briefSummary":248,"conditions":249,"keywords":250,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":38},"100552879","healthy-stool-volunteer-donors-for-fecal-microbiota-transplantation-trials-100552879","NCT06478823","Healthy Stool Volunteer Donors for Fecal Microbiota Transplantation Trials","VIOLONSEL","Inclusion Criteria:\n\n\\- Age ≥ 18 years and \\\u003C 50 years\n\n* 17 kg\u002Fm² \\\u003C body mass index \\\u003C 30 kg\u002Fm²\n* Regular bowel movement defined as at least 1 stool every other day and maximum 2 stools per day\n* Subject with health insurance (AME excepted)\n* Informed written consent\n\nExclusion Criteria:\n\nDefinitive non-inclusion criteria:\n\n1. Infectious risk :\n\n   \\- Known HIV, HBV, HCV, HTLV infection\n\n   \\- Residence of more than 2 years in the intertropics zone within the previous 5 years\n\n   \\- Hospitalization abroad for more than 24 hours in the last 12 months (including a member of the healthy volunteers donor's entourage)\n\n   \\- Risk factors for Creutzfeldt-Jakob disease (history: treatment with extractive growth hormone, a family case of transmissible spongiform subacute encephalopathy, surgery with opening of the dura or neurosurgery or invasive brain exploration before 1 January 1995, stay in United Kingdom for a duration greater than 1 year cumulatively between 1980 and 1996 or the presence of neurological or neuropsychiatric scalable recent clinical signs)\n   * Previous history of typhoid fever, tuberculosis and malaria\n   * Past or current injection drug user or regular use of other drug\n2. Gastrointestinal disease:\n\n   \\- Personal or 1st degree family history of: inflammatory bowel disease or celiac disease\n\n   \\- Personal history of irritable bowel syndrome, idiopathic chronic constipation or chronic diarrhea\n\n   \\- Previous history of gastrointestinal neoplasia or polyps\n\n   \\- Family history of 1st degree gastrointestinal neoplasia or polyps before age 60\n3. 1st degree family history of one of the following autoimmune or inflammatory disease : inflammatory arthritis, psoriasis, multiple sclerosis, type I diabetes, spondylitis, lupus and Basedow disease\n\n   \\- If family history unknown in the first degree, the donor is not eligible\n4. Previous history of :\n\n   * Subject prone to hemorrhoids (at least 1 event within the previous 1 year)\n   * Subject with an active chronic illness (except active chronic mild allergic disease o (example: allergic rhinitis, chronic eczema…))\n\n     * Diagnosis of Gilbert's syndrome done by screening is not a chronic disease. The healthy volunteer donor will therefore remain eligible.\n   * Serious allergy requiring hospitalization within the previous 12 months\n   * Curative long-term treatment\n   * Severe allergy requiring hospitalization in the last 12 months\n   * Allogeneic human or animal tissue or organ transplant\n   * 5- Factors that may affect the composition of the intestinal microbiota:\n   * Special Diet (example: gluten-free...)\n   * Lactose-free, vegetarian and vegan diets are permitted.\n   * Pregnancy or breastfeeding\n   * Taking immunosuppressants (eg calcineurin inhibitors, corticosteroids, biological agents, etc.)\n   * Antineoplastic chemotherapy\n\n6- Subject under legal protection 7- Participation in any other interventional study except studies for stool donation Temporary non-inclusion criteria\n\n1. Infectious risk :\n\n   * Unprotected sexual intercourse with a new partner in the previous 4 months and\u002For sexual intercourse with several different persons within the previous 4 months\n   * sexual partner who has had more than 1 partner within the previous 4 months and\u002For\n   * sexual transmitted infection within the previous 4 months (healthy volunteer donor himself or sexual partner)\n   * Sexual relationship in exchange for money or drugs in the last 12 months. (healthy volunteer donor himself or sexual partner)\n   * Sexual relationship with a partner with positive serology for HIV, viral hepatitis B or C, in the last 6 months.\n   * Sexual relationship with a partner who has used intravenous drugs, doping substances\n   * Hospitalization abroad for more than 24 hours in the last 12 months (healthy volunteer or entourage)\n   * Travelling within the previous 3 months except : Germany, Austria, Belgium, Spain, Finland, Ireland, Italia, Luxembourg, Netherland, Portugal, Greece, Slovenia, Cyprus, Malta, Slovakia, Estonia , Bulgaria, Croatia , Hungary, Latvia , Lithuania, Poland , Romania, Czech Republic, the United Kingdom, Denmark, Norway, Sweden, Switzerland, USA or Canada.\n   * Blood transfusion, piercing (including earrings) or tattoo within the previous 4 months\n   * Surgery (all types) or hospitalization within the previous 4 months\n   * Person living under the same roof with an infectious or contagious disease (i.e who have been hospitalized) within the previous 4 months\n   * Blood exposure accident (for wound, pricking or projection ...) within the previous 4 months\n   * Dental care within the previous 7 days\n   * Gastroenteritis within the previous 3 months (defined by acute onset of diarrhea (\\> 3 soft or liquid stools per day) and duration \\\u003C one week)\n   * Episode of infection or skin infection\u002Flesion within the previous 15 days 2-Risk linked to Covid-19\n   * Confirmed infection in the previous 28 days (after symptoms have ceased)\n   * Clinical signs of suspected infection (chill, cough, fever, dyspnea, myalgia, asthenia, malaise, pharyngeal pain, anosmia , ageusia, rhinorrhea, chest pain, headache, diarrhea) in the previous 28 days (after the end of symptoms)\n   * Having been in risky contact (according to the definition of Santé Publique France with a person whose infection is confirmed or suspected: \"14 days after the last risky contact: if the recommended screening tests in the event of risky contact between D15-D28 are negative \"In the 28 days preceding inclusion in the absence of a screening test. Healthcare professionals using recommended protective measures with COVID patients are not considered high-risk contacts 3- Monkeypox risk\n   * Confirmed or suspected infection within the previous 42 days ( after beginning of symptoms)\n   * Risky contact with a person with confirmed or suspected infection within the previous 21 days (from the date of last contact)\n   * Person who received the vaccine Imvanex within the previous 28 days ( after the last injection).\n\n     4- vaccination in the previous 15 days\n\n     5- Factors that may affect the composition of the intestinal microbiota:\n   * Taking antibiotic or antifungal (oral) in the previous 3 months before donation\n   * Taking non-steroidal anti-inflammatory drugs (oral) in the previous month before donation\n   * Taking corticosteroids (oral) in the previous 4 weeks before donation. Corticosteroids allowed if taken more than 4 weeks before donation. and not for an autoimmune or inflammatory disease.\n\nTemporary or permanent exclusion criteria:\n\n\\- At each visit of the donation period, the temporary or definitive exclusion criteria (identical to the temporary or definitive non-inclusion criteria) will be rechecked","49 Years",{"count":246,"type":19},400,[138],"Currently, ANSM recommendations govern FMT (Fecal Microbiota Transplantation) in clinical trials. The collection and validation of these stool donations as part of the trials is complex and not very efficient. It therefore seems essential to identify the limiting factors and the characteristics of Healthy Volunteer Donors to optimize the number of valid stool donations.",[25],[251,252,253],"Healthy Volunteer stool Donors","Stools donations","Fecal microbiota transplantation","2024-07-22",{"date":256,"type":30},"2024-07-23",{"date":258,"type":30},"2024-07-08",{"date":260,"type":19},"2030-05",{"name":262,"class":37},"Assistance Publique - Hôpitaux de Paris",{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":46,"sex":15,"minAge":269,"maxAge":197,"enrollmentInfo":270,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":272,"conditions":273,"keywords":279,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":38},"100536929","the-gut-lung-axis-and-respiratory-illness-in-children-100536929","NCT06271213","The Gut-Lung Axis and Respiratory Illness in Children","Inclusion Criteria:\n\n* Any infant\u002Fchild\u002Fyoung person admitted to the RHC, Glasgow for an elective bronchoscopy or GI endoscopy.\n* Any infant\u002Fchild attending for an emergency\u002Felective orthopaedic operation without active respiratory or gastrointestinal conditions or receiving treatment for either condition. (Age range birth to 16 years for all groups recruited).\n* Any child attending respiratory department at RHC who can induce sputum and is having a blood sample taken, with latter part of standard of care.\n* Any infant\u002Fchild\u002Fyoung person admitted to RHC for a clinical care appointment with Asthma\u002Fwheeze before commencement of biologics therapy (treatment group).\n* Any child admitted to RHC with asthma\u002Fwheeze not indicated for biologic therapy (asthma control group).\n\nExclusion Criteria:\n\n* Use of antibiotics by the day of admission or have used antibiotics in the previous month (unless prophylactic antibiotics \\> 1 month use).\n* Any person 17 years old and above.\n* Any child known to be infected with, or at high risk of having had exposure to HIV, hepatitis B or hepatitis C viruses\n* . Any child and\u002For parent\u002Fguardian who cannot understand the English language where consent would be unethical.\n* Any child with Asthma currently receiving Biologics therapy (unless recruited via bronchoscopy route).","0 Years",{"count":271,"type":19},150,"The goal of this single-centre observational study conducted at the Royal Hospital for Children in Glasgow, Scotland, is to employ a multi-omics approach to investigate the \"gut-lung axis\" in health and disease.\n\nPart A is a cross-sectional study design investigating the postulated bidirectional link between the gut and lung microbiomes in children suffering from respiratory or gastrointestinal conditions. Children with no GI or respiratory issues attending for orthopaedic care will be used as a benchmark for a healthy gut-lung axis. The main questions we aim to answer are:\n\n* What does a healthy gut-lung axis look like?\n* Do children with respiratory issues show an altered gut microbiome?\n* Do children with GI issues show an altered lung microbiome?\n\nPart B is a longitudinal study design, that aims to assess the effects of biologics on the gut-lung axis by comparing the gut and lung microbiomes in children with asthma at two time-points who are indicated to start biologics therapy (Asthma treatment) or will not receive biologics therapy (asthma control).\n\nParticipants will provide:\n\n* airway samples (to investigate the lung microbiome)\n* blood samples (to assess inflammatory and metabolic factors which may mediate communication between the two sites) whilst under general anaesthetic for a treatment related to their standard of care\n* stool samples (to assess gut microbiome)\n* dietary information (food diary and\u002For food frequency questionnaire) to assess relationships between diet and the gut-lung axis.",[274,275,276,277,25,278],"Respiration Disorders","Respiratory Disease","Asthma in Children","Wheezing","Healthy",[280,228,281,282],"Gut-Lung Axis","Multi-omics","Children","2024-02-14",{"date":285,"type":30},"2024-02-21",{"date":287,"type":30},"2024-02-04",{"date":289,"type":19},"2028-05-01",{"name":291,"class":37},"NHS Greater Glasgow and Clyde"]